No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
EBS250117P17000
- 0.00
- 0.000.00%
15min DelayClose Jan 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest17.00Strike Price0.00Turnover0.00%IV-51.92%PremiumJan 17, 2025Expiry Date5.81Intrinsic Value100Multiplier-10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Express News | Emergent BioSolutions Inc - First Interim Analysis of Mosa Trial Expected by End of Q1 2025
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Express News | Enrollment Starts in Africa Cdc-Led Mpox Therapeutic Study (Mosa)
Emergent BioSolutions Outlines Growth at J.P. Morgan Conference
Express News | Emergent BioSolutions Shares up 4.3% on Gaining Commercial Rights for Hikma's Opioid Overdose Treatment
Express News | Emergent BioSolutions Gains Exclusive Commercial Rights to Kloxxado® (Naloxone Hci) Nasal Spray From Hikma Pharmaceuticals